OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-endProactive Investors • 01/29/25
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 11/15/24
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conferenceProactive Investors • 10/30/24
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMIProactive Investors • 10/26/24
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialProactive Investors • 10/23/24
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainGlobeNewsWire • 10/23/24
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatmentProactive Investors • 10/16/24
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 08/23/24
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/15/24
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseGlobeNewsWire • 08/06/24
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseGlobeNewsWire • 07/10/24
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)GlobeNewsWire • 04/30/24
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventProactive Investors • 04/09/24
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024GlobeNewsWire • 04/08/24